Samsung Biologics said it would participate in CPhI (Convention on Pharmaceutical Ingredients) Worldwide 2021 to promote its competitiveness and attract prospective customers.

CPhI is the world's largest biopharmaceutical conference. This year’s event will be held on- and offline for the first time since the Covid-19 outbreak.

Milan, Italy, will host the event from Tuesday to Thursday.

During the conference, Samsung Biologics will provide new customer experiences and business networking with various contents and events under the theme of "Infinite Possibilities for the Next Decade," the company said in a news release on Tuesday.

Samsung Biologics has also set up a booth at the convention and installed a large panoramic panel that allows visitors to see the company's innovations and achievements at a glance and highlighted its competitiveness in the contract development manufacturing organization (CDMO) business under four themes.

The four themes are the competitiveness of its fourth plant, S-Cellerate, business portfolio diversification through multimodality, and end-to-end service.

Introducing its fourth plant under construction, the company explained that the factory is a super plant where all processes from cell line development to commercial production are possible by combining state-of-the-art equipment and optimized processes.

When the fourth plant starts operation, Samsung Biologics will secure the production capacity of 620,000 liters, the company said.

S-Cellerate is a service that optimizes and supports each process from the initial development stage to the investigational new drug (IND) application and from the late development stage to the biologics license application (BLA).

Through these innovations, the customer can reduce the time it takes to develop a biopharmaceutical by up to nine months, the company said.

Commenting on plans to diversify its business portfolio through multimodality, the company said that it would produce various types of pharmaceuticals, such as cell and gene therapy products and vaccines, in one factory,

"We are expanding our facilities for the production of mRNA drug substances intending to start operation in the first half of 2022," a company official said.

Besides, the company explained that its end-to-end service provides a one-stop service from the initial stage of biopharmaceutical development to commercial production.

"We opened a CDO R&D Center in San Francisco in 2020 to strengthen our global consignment development capabilities, and plan to further expand the CMO production scale by building the second Bio Campus in Songdo, Incheon," the company official said.